Lieberman Phil, Camargo Carlos A, Bohlke Kari, Jick Hershel, Miller Rachel L, Sheikh Aziz, Simons F Estelle R
Division of Allergy/Immunology, Department of Medicine, University of Tennessee College of Medicine, Germantown, Tennessee, USA.
Ann Allergy Asthma Immunol. 2006 Nov;97(5):596-602. doi: 10.1016/S1081-1206(10)61086-1.
To improve understanding of the epidemiology of anaphylaxis.
We performed a qualitative review by hand of the major epidemiology studies of anaphylaxis. This review was restricted to articles in the English language.
Articles chosen were selected by the committee and dated back to 1968. There was no specific criterion used for selection except the determination of the members of the committee.
Data on anaphylaxis incidence and prevalence are sparse and often imprecise. Findings are based on diverse study designs and are not entirely comparable. These factors have contributed to widely varying estimates of the frequency of this important condition. The roundtable discussion led to an improved estimation of the frequency of anaphylaxis: approximately 50 to 2,000 episodes per 100,000 persons or a lifetime prevalence of 0.05% to 2.0%. The largest number of incident cases is among children and adolescents. In addition to underdiagnosis, we noted undertreatment, especially for those at highest risk (ie, those without immediate access to treatment with epinephrine).
Anaphylaxis is a relatively common problem, affecting up to 2% of the population. Further data on epinephrine dispensing could improve current estimates. Another way to improve current understanding would be through better population-based study designs in different geographic regions. A recurring theme was the importance of broader access to self-injectable epinephrine for high-risk populations. An improved epidemiologic understanding of this disorder would aid ongoing efforts to reduce morbidity and mortality from anaphylaxis and could provide important clues for primary prevention.
提高对过敏反应流行病学的认识。
我们手工对过敏反应的主要流行病学研究进行了定性综述。该综述仅限于英文文章。
所选文章由委员会挑选,可追溯至1968年。除委员会成员的判定外,没有使用特定的选择标准。
关于过敏反应发病率和患病率的数据稀少且往往不准确。研究结果基于多样的研究设计,并非完全可比。这些因素导致对这一重要病症发生率的估计差异很大。圆桌讨论得出了对过敏反应发生率的改进估计:每10万人中约有50至2000例发作,或终生患病率为0.05%至2.0%。发病病例数最多的是儿童和青少年。除了诊断不足外,我们还注意到治疗不足,尤其是对那些风险最高的人群(即那些无法立即获得肾上腺素治疗的人群)。
过敏反应是一个相对常见的问题,影响高达2%的人口。关于肾上腺素配给的更多数据可以改进当前的估计。另一种改善当前认识的方法是通过在不同地理区域采用更好的基于人群的研究设计。一个反复出现的主题是高危人群更广泛地获得可自行注射肾上腺素的重要性。对这种疾病的流行病学认识的提高将有助于正在进行的降低过敏反应发病率和死亡率的努力,并可为一级预防提供重要线索。